EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals (NASDAQ: EYPT), a retinal disease therapeutics company, announced the granting of inducement stock options to seven new employees on July 15, 2025. The awards, issued outside the company's 2023 Long-Term Incentive Plan, total 63,900 shares with an exercise price of $9.84 per share.
The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting monthly over three years, contingent on continued employment.
EyePoint Pharmaceuticals (NASDAQ: EYPT), un'azienda specializzata in terapie per le malattie retiniche, ha annunciato la concessione di opzioni azionarie di incentivo a sette nuovi dipendenti il 15 luglio 2025. Le assegnazioni, emesse al di fuori del Piano di Incentivi a Lungo Termine 2023 dell'azienda, ammontano a un totale di 63.900 azioni con un prezzo di esercizio di 9,84 $ per azione.
Le opzioni hanno una durata di dieci anni e seguono un piano di maturazione quadriennale, con il 25% che matura dopo il primo anno e il restante che matura mensilmente nei successivi tre anni, a condizione che il rapporto di lavoro continui.
EyePoint Pharmaceuticals (NASDAQ: EYPT), una compañía de terapias para enfermedades retinianas, anunció la concesión de opciones sobre acciones como incentivo a siete nuevos empleados el 15 de julio de 2025. Las adjudicaciones, otorgadas fuera del Plan de Incentivos a Largo Plazo 2023 de la empresa, suman un total de 63,900 acciones con un precio de ejercicio de $9.84 por acción.
Las opciones tienen un plazo de diez años y siguen un calendario de adquisición de derechos de cuatro años, con un 25% adquirido tras el primer año y el resto adquirido mensualmente durante los siguientes tres años, condicionado a la continuidad del empleo.
EyePoint Pharmaceuticals(NASDAQ: EYPT)는 망막 질환 치료제 회사로서 2025년 7월 15일 7명의 신입 직원에게 유인 주식 옵션을 부여했다고 발표했습니다. 이 수상은 회사의 2023년 장기 인센티브 계획 외부에서 발행되었으며, 총 63,900주로 주당 행사가격은 $9.84입니다.
옵션은 10년 기간이며 4년 베스팅 스케줄을 따릅니다. 1년 후 25%가 베스팅되고 나머지는 3년 동안 매월 베스팅되며, 계속 근무하는 조건입니다.
EyePoint Pharmaceuticals (NASDAQ : EYPT), une société spécialisée dans les traitements des maladies rétiniennes, a annoncé l'octroi d'options d'achat d'actions incitatives à sept nouveaux employés le 15 juillet 2025. Les attributions, émises en dehors du Plan d'Incentive à Long Terme 2023 de l'entreprise, totalisent 63 900 actions avec un prix d'exercice de 9,84 $ par action.
Les options ont une durée de dix ans et suivent un calendrier d'acquisition sur quatre ans, avec 25 % qui devient acquis après la première année et le reste acquis mensuellement sur les trois années suivantes, sous réserve de la poursuite de l'emploi.
EyePoint Pharmaceuticals (NASDAQ: EYPT), ein Unternehmen für Therapien bei Netzhauterkrankungen, gab am 15. Juli 2025 die Gewährung von Anreiz-Aktienoptionen an sieben neue Mitarbeiter bekannt. Die Zuteilungen, die außerhalb des Long-Term Incentive Plans 2023 des Unternehmens erfolgen, umfassen insgesamt 63.900 Aktien mit einem Ausübungspreis von 9,84 $ pro Aktie.
Die Optionen haben eine Laufzeit von zehn Jahren und folgen einem vierjährigen Vesting-Plan, bei dem 25 % nach dem ersten Jahr vesten und der Rest monatlich über drei Jahre verteilt vestet, vorausgesetzt, die Beschäftigung wird fortgesetzt.
- None.
- None.
WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 63,900 shares of EyePoint common stock to seven new employees. The stock options were granted on July 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema (DME).
The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
For EyePoint:
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
What stock options did EyePoint Pharmaceuticals (EYPT) grant to new employees in July 2025?
What is the vesting schedule for EyePoint's (EYPT) July 2025 employee stock options?
What is the exercise price of EyePoint's (EYPT) July 2025 inducement grants?
How long is the term for EyePoint's (EYPT) July 2025 employee stock options?
